Twin and Triplet Drugs in Opioid Research

被引:38
作者
Fujii, Hideaki [1 ]
机构
[1] Kitasato Univ, Sch Pharm, Minato Ku, Tokyo 1088641, Japan
来源
CHEMISTRY OF OPIOIDS | 2011年 / 299卷
关键词
Dual action; Increment of potency; Receptor dimerization; Twin drug; Triplet drug; RECEPTOR-BINDING PROPERTIES; LINKED BIFUNCTIONAL PEPTIDES; ANTAGONIST BIVALENT LIGANDS; PROTEIN-COUPLED RECEPTORS; MESSAGE-ADDRESS CONCEPT; RAT SPINAL-CORD; SUBSTANCE-P; MORPHINE-TOLERANCE; HIGH-AFFINITY; I-2-IMIDAZOLINE RECEPTORS;
D O I
10.1007/128_2010_76
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Twin and triplet drugs are defined as compounds that contain respectively two and three pharmacophore components exerting pharmacological effects in a molecule. The twin drug bearing the same pharmacophores is a "symmetrical twin drug", whereas that possessing different pharmacophores is a "nonsymmetrical twin drug." In general, the symmetrical twin drug is expected to produce more potent and/or selective pharmacological effects, whereas the nonsymmetrical twin drug is anticipated to show both pharmacological activities stemming from the individual pharmacophores (dual action). On the other hand, nonsymmetrical triplet drugs, which have two of the same pharmacophores and one different moiety, are expected to elicit both increased pharmacological action and dual action. The two identical portions could bind the same receptor sites simultaneously while the third portion could bind a different receptor site or enzyme. This review will mainly focus on the twin and triplet drugs with an evaluation of their in vivo pharmacological effects, and will also include a description of their pharmacology and synthesis.
引用
收藏
页码:239 / 275
页数:37
相关论文
共 165 条
  • [1] ABDELHAMID EE, 1991, J PHARMACOL EXP THER, V258, P299
  • [2] agase H, 2002, [No title captured], Patent No. [JP 2002332284A, 2002332284]
  • [3] Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors
    Agnes, Richard S.
    Lee, Yeon Sun
    Davis, Peg
    Ma, Shou-Wu
    Badghisi, Hamid
    Porreca, Frank
    Lai, Josephine
    Hruby, Victor J.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (10) : 2868 - 2875
  • [4] Akbarzadeh A, 1999, BIOTECHNOL APPL BIOC, V30, P139
  • [5] Anges RS, 2008, PEPTIDES, V29, P1413
  • [6] Multiple Ligands in opioid research
    Ballet, Steven
    Pietsch, Markus
    Abell, Andrew D.
    [J]. PROTEIN AND PEPTIDE LETTERS, 2008, 15 (07) : 668 - 682
  • [7] BARLOW JJ, 1991, J MED CHEM, V34, P3150
  • [8] Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats
    Beardsley, PM
    Howard, JL
    Shelton, KL
    Carroll, FI
    [J]. PSYCHOPHARMACOLOGY, 2005, 183 (01) : 118 - 126
  • [9] A bivalent ligand (KDN-21) reveals spinal δ and κ opioid receptors are organized as heterodimers that give rise to δ1 and κ2 phenotypes.: Selective targeting of δ-κ heterodimers
    Bhushan, RG
    Sharma, SK
    Xie, ZH
    Daniels, DJ
    Portoghese, PS
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (12) : 2969 - 2972
  • [10] DEVELOPMENT OF 1,4-BENZODIAZEPINE CHOLECYSTOKININ TYPE-B ANTAGONISTS
    BOCK, MG
    DIPARDO, RM
    EVANS, BE
    RITTLE, KE
    WHITTER, WL
    GARSKY, VM
    GILBERT, KF
    LEIGHTON, JL
    CARSON, KL
    MELLIN, EC
    VEBER, DF
    CHANG, RSL
    LOTTI, VJ
    FREEDMAN, SB
    SMITH, AJ
    PATEL, S
    ANDERSON, PS
    FREIDINGER, RM
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (26) : 4276 - 4292